Trial · NCT03041701
Adverse events492
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 492
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal distension | Gastrointestinal disorders | Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg | 3 | 7 | 4 |
| other | Abdominal distension | Gastrointestinal disorders | Phase 1 Dose Level 2 Dose Escalation Dasatinib 60 mg/m^2 Twice Daily (BID)/Ganitumab 18 mg/kg | 1 | 6 | 1 |
| other | Abdominal distension | Gastrointestinal disorders | Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg | 0 | 1 | 0 |
| other | Abdominal pain | Gastrointestinal disorders | Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg | 3 | 7 | 5 |
| other | Abdominal pain | Gastrointestinal disorders | Phase 1 Dose Level 2 Dose Escalation Dasatinib 60 mg/m^2 Twice Daily (BID)/Ganitumab 18 mg/kg | 1 | 6 | 1 |
| other | Abdominal pain | Gastrointestinal disorders | Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg | 0 | 1 | 0 |
| other | Activated partial thromboplastin time prolonged | Investigations | Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg | 1 | 7 | 2 |
| other | Activated partial thromboplastin time prolonged | Investigations | Phase 1 Dose Level 2 Dose Escalation Dasatinib 60 mg/m^2 Twice Daily (BID)/Ganitumab 18 mg/kg | 2 | 6 | 3 |
| other | Activated partial thromboplastin time prolonged | Investigations | Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg | 0 | 1 | 0 |
| other | Acute kidney injury | Renal and urinary disorders | Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg | 1 | 7 | 2 |
| other | Acute kidney injury | Renal and urinary disorders | Phase 1 Dose Level 2 Dose Escalation Dasatinib 60 mg/m^2 Twice Daily (BID)/Ganitumab 18 mg/kg | 0 | 6 | 0 |
| other | Acute kidney injury | Renal and urinary disorders | Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg | 0 | 1 | 0 |
| other | Alanine aminotransferase increased | Investigations | Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg | 3 | 7 | 6 |
| other | Alanine aminotransferase increased | Investigations | Phase 1 Dose Level 2 Dose Escalation Dasatinib 60 mg/m^2 Twice Daily (BID)/Ganitumab 18 mg/kg | 2 | 6 | 11 |
| other | Alanine aminotransferase increased | Investigations | Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg | 0 | 1 | 0 |
| other | Alkaline phosphatase increased | Investigations | Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg | 1 | 7 | 1 |
| other | Alkaline phosphatase increased | Investigations | Phase 1 Dose Level 2 Dose Escalation Dasatinib 60 mg/m^2 Twice Daily (BID)/Ganitumab 18 mg/kg | 2 | 6 | 6 |
| other | Alkaline phosphatase increased | Investigations | Phase 2 Dose Level 1 Maximum Tolerated Dose Dasatinib 60 mg/m^2 Every Day (QD)/ Ganitumab 18 mg/kg | 0 | 1 | 0 |
| other | Allergic reaction | Immune system disorders | Phase 1 Dose Level 1 Dose Escalation Dasatinib 60 mg/m^2 Every Day (QD)/Ganitumab 18 mg/kg | 1 | 7 | 1 |
| other | Allergic reaction | Immune system disorders | Phase 1 Dose Level 2 Dose Escalation Dasatinib 60 mg/m^2 Twice Daily (BID)/Ganitumab 18 mg/kg | 0 | 6 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03041701/events